CN114668757B - Application of pseudolaric acid B in preparing medicine for preventing and/or treating malignant tumor - Google Patents
Application of pseudolaric acid B in preparing medicine for preventing and/or treating malignant tumor Download PDFInfo
- Publication number
- CN114668757B CN114668757B CN202210318949.0A CN202210318949A CN114668757B CN 114668757 B CN114668757 B CN 114668757B CN 202210318949 A CN202210318949 A CN 202210318949A CN 114668757 B CN114668757 B CN 114668757B
- Authority
- CN
- China
- Prior art keywords
- cells
- human
- acid
- pseudolaric
- pseudolaric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Application of cortex pseudolaricis propionic acid in preparing medicine for preventing and/or treating malignant tumor relates to the field of new medical application. The invention discloses a new application of pseudolaric acid B in preparing a medicament for preventing and/or treating malignant tumor; the malignant tumor includes: glioma, liver cancer, breast cancer and ovarian cancer; the concentration of the pseudolaric acid B is 12.5-200 umol/L. Experiments prove that the pseudolaric acid B can effectively kill various malignant tumor cells such as human brain glioma cells, human liver cancer cells, human breast cancer cells, human ovarian cancer cells and the like in a concentration dependent manner, and has a certain dose-effect relationship; the pseudolaric acid B has low toxicity to normal human cells, and can activate autophagy flow in human glioma cells to kill the human glioma cells. The invention exploits the new application of pseudolaric acid B and provides a new therapeutic scheme for treating various malignant tumor cells.
Description
Technical Field
The invention relates to the technical field of new medical application, in particular to application of pseudolaric acid B in preparing a medicine for preventing and/or treating malignant tumor.
Background
Cancer is medically collectively called malignant tumor, is a complex serious disease severely threatening human health, and is the second leading cause of death in humans worldwide, next to cardiovascular and cerebrovascular diseases.
Human brain glioma is the most common primary malignant tumor in the cranium, can be seen in all age groups, is frequently seen in adults, has no obvious difference in the morbidity of men and women, and has the characteristics of high disability rate, high recurrence rate and high death rate. The treatment of human brain glioma mainly adopts surgery to remove tumor, and combines postoperative radiotherapy and chemotherapy. However, the average post-operative survival of patients with glioblastoma (high grade) graded as grade III and IV by WHO is no more than 1 year. At present, the treatment effect of Temozolomide (Temozolomide) serving as a first-line chemotherapeutic medicament in human glioma treatment on high-grade gliomas (WHO is classified into III-IV levels) is not ideal all the time, and compared with the average survival time of patients with high-grade gliomas treated by a simple surgical operation, the average survival time of the patients can be prolonged by 3-5 months by combining Temozolomide treatment after operation. Therefore, there is no effective drug for chemotherapy of human brain glioma.
Liver cancer is classified into primary and secondary, and refers to malignant tumor derived from liver cells and hepatobiliary tract cells, which is one of common malignant tumors in China. The symptoms of early liver cancer are usually non-specific, while the symptoms of middle and late liver cancer are more, and the common clinical manifestations are as follows: pain in liver area, abdominal distention, anorexia, debilitation, emaciation, progressive liver enlargement or epigastric mass; some patients also have low fever, jaundice, diarrhea, upper gastrointestinal bleeding, etc. The current liver cancer treatment method mainly comprises the following steps: surgical treatment, vascular intervention embolism, ablation, radiation treatment, targeted treatment, traditional Chinese medicine treatment and the like. Therefore, there is no effective drug for treating liver cancer.
Breast cancer is a malignant tumor that occurs in the mammary epithelium or ductal epithelium, the etiology of which is not completely understood, and may be related to family history and breast cancer related genes, reproductive factors, sex hormones, nutrition, diet, environmental factors, and the like. Most of early breast cancers have no obvious symptoms, and most of breast tumors have no pain, and later breast skin 'litter disease' or orange peel-like changes, axillary lymphadenectasis and the like appear. The treatment method of the breast cancer mainly comprises the following steps: surgical excision, chemotherapy, radiation therapy, endocrine therapy, and targeted therapy. Wherein, the operation treatment is suitable for patients with complete excision of tumor, and according to pathological stage, pathological type and molecular typing, whether other treatment means are combined is considered; targeted therapy: the gene immunohistochemical method detects more than HER 23+ or the FISH method detects the positive HER2 amplification; radiation therapy: irradiating the local and lymphatic drainage areas of the mammary gland by using high-energy X rays; endocrine treatment: triphenoxyamine and letrozole are commonly used. Therefore, there is no effective drug for the treatment of breast cancer.
Ovarian cancer is one of the common malignant tumors of female reproductive organs, and refers to malignant diseases occurring in ovaries, and the incidence rate is second only to cervical cancer and endometrial cancer. Ovarian cancer is the most common epithelial cancer, and is secondarily malignant germ cell tumor, wherein the death rate of the ovarian epithelial cancer accounts for the first place of various gynecological tumors, and can cause serious threat to female life. The early stage of ovarian cancer is asymptomatic, and the late stage of ovarian cancer can generate digestive tract symptoms such as lower abdomen discomfort, abdominal distension, appetite reduction and the like, and the treatment mode mainly comprises the following steps: surgical resection, drug treatment and radiation treatment, the overall prognosis is poor. Thus, there is a lack of effective drugs in the treatment of ovarian cancer.
Cortex pseudolaricis propionic acid (PseudolaricAcid C) is a natural small molecular compound extracted from dried root bark or near root bark of herba Lysimachiae Christinae, which is white crystal, insoluble in water, and easily soluble in organic solvent such as DMSO. The molecular formula: c (C) 21 H 26 O 7 The method comprises the steps of carrying out a first treatment on the surface of the Molecular weight: 390; CAS number: 82601-41-0. The cortex pseudolaricis propionic acid (PseudolaricAcid C) has the characteristics of convenient material taking, low price and the like. Cortex pseudolaricis can be used for treating localized neurodermatitis. However, the use, mechanism of action, etc. of the natural small molecular compound pseudolaric acid extracted from pseudolaric bark are not known, and particularly the prevention and/or treatment of malignant tumors by pseudolaric acid has not been reported.
Disclosure of Invention
The invention aims to provide a new application of pseudolaric acid B in preparing medicines for preventing and/or treating malignant tumors.
The technical scheme adopted by the invention for solving the technical problems is as follows:
the application of the pseudolaric acid B in preparing the medicines for preventing and/or treating malignant tumor is disclosed.
As a preferred embodiment, the malignant tumor comprises: glioma, liver cancer, breast cancer and ovarian cancer.
As a preferred embodiment, the concentration of the pseudolaric Pi Bing acid is 12.5-200 umol/L.
As a more preferable embodiment, the concentration of the pseudolaric Pi Bing acid is 25-50 umol/L.
As the most preferred embodiment, the concentration of the pseudolaric Pi Bing acid is 25umol/L.
The beneficial effects of the invention are as follows:
experiments prove that the pseudolaric acid B can effectively kill various malignant tumor cells such as human brain glioma cells, human liver cancer cells, human breast cancer cells, human ovarian cancer cells and the like in a concentration dependent manner, and has a certain dose-effect relationship. Meanwhile, experiments prove that the pseudolaric acid B has low toxicity to normal human cells, the pseudolaric acid B can activate autophagy flow in human glioma cells, and the pseudolaric acid B can kill human glioma cells by activating autophagy flow in human glioma cells.
The invention discovers that the pseudolaric acid B can prevent and/or treat various malignant tumor cells such as human brain glioma cells, human liver cancer cells, human breast cancer cells, human ovarian cancer cells and the like, exploits the novel application of the pseudolaric acid B, and provides a novel therapy and treatment scheme for treating various malignant tumor cells such as human brain glioma cells, human liver cancer cells, human breast cancer cells, human ovarian cancer cells and the like.
Drawings
FIG. 1 shows the proliferation inhibition effect of pseudolaric acid on human brain glioma cells U251 in example 1.
FIG. 2 shows the proliferation inhibition effect of pseudolaric acid on human brain glioma cells U87 in example 1.
FIG. 3 shows the proliferation inhibition effect of pseudolaric acid on human brain glioma cells U118 in example 1.
FIG. 4 shows the toxic effect of pseudolaric acid on human umbilical vein epithelial cells HUVEC in example 2.
FIG. 5 shows the effect of pseudolaric acid on the regulation of autophagy-related proteins in human glioma cells U87 in example 3.
FIG. 6 shows the activation of autophagy flow in human glioma cells U87 by pseudolaric acid B in example 3.
FIG. 7 shows the inhibition of pseudolaric acid-induced human brain glioma cell death by 3MA and Bafulomycin A1 of example 3.
FIG. 8 shows the regulatory effect of 3MA and Baofuromycin A1 on pseudolaric acid-induced proteins in example 3.
FIG. 9 shows the proliferation inhibition effect of pseudolaric acid on human hepatoma cells in example 4.
FIG. 10 shows the proliferation inhibition effect of the pseudolaric Pi Bingsuan on breast cancer cells in example 5.
FIG. 11 shows the proliferation inhibitory effect of pseudolaric acid on human ovarian cancer cells in example 6.
Detailed Description
The technical solutions of the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention, and it is apparent that the described embodiments are only some embodiments of the present invention, not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
The material sources are as follows:
cortex pseudolaricis propionic acid, purchased from Shanghai Seiyaka Biotechnology Co., ltd, is formulated into desired concentration with DMSO solution when used.
Human brain glioma cells U251, U87 and U118 were all purchased from gikava biotechnology company, china.
Human umbilical vein epithelial cells HUVEC were purchased from gikava biotechnology company, china.
Human hepatoma cells Hep3B, breast cancer cells MB-231, and human ovarian cancer cells A2780 were all purchased from Jikai Biotechnology Co, china.
EXAMPLE 1 proliferation inhibition of Hibiscus syriacus bark propionic acid on human brain glioma cells
Human brain glioma cells U251, U87 and U118 are respectively inoculated into DMEM culture medium in a 96-well plate, incubated with different concentrations of pseudolaric acid B (12.5 umol/L, 25umol/L, 50umol/L, 100umol/L and 200 umol/L) for 48 hours in a carbon dioxide incubator overnight, and the proliferation capacity of the cells is detected by an MTT method, and the results show that the survival rate of the U251 cells is 96.67%, 91.97%, 68.75%, 43.59% and 34.05% respectively in FIG. 1 and Table 1; as shown in fig. 2 and table 2, U87 cell viability was 97.19%, 91.73%, 69.27%, 46.51% and 31.94%, respectively; as shown in FIG. 3 and Table 3, U118 cell viability was 98.36%, 93.04%, 67.57%, 44.42% and 34.60%, respectively.
As shown by the detection result, the survival rate of the glioma cells correspondingly decreases with the increase of the propionic acid concentration of the cortex pseudolaricis. From this, it was confirmed that pseudolaric acid can kill glioma cells in a concentration-dependent manner.
TABLE 1 proliferation inhibition of human brain glioma cell U251 by pseudolaric acid B (.: p < 0.01)
TABLE 2 proliferation inhibition of human brain glioma cells U87 by pseudolaric acid B (< 0.01. P)
Table 3 proliferation inhibition of human brain glioma cell U118 by pseudolaric acid B (< 0.05: p < 0.01)
EXAMPLE 2 toxic Effect of pseudolaric acid on normal cells
In order to examine the toxic effect of pseudolaric acid on normal cells, human umbilical vein epithelial cells HUVEC were inoculated into DMEM medium in 96-well plates, and incubated with different concentrations of pseudolaric acid (12.5, 25, 50, 100, 200) for 48 hours in a carbon dioxide incubator overnight, and then tested for cell proliferation by MTT method, and the viability of HUVEC cells was 100%, 99.15%, 95.84%, 89.80% and 82.42%, respectively, as shown in FIG. 4 and Table 4.
As shown by the detection results, compared with the survival rates of the human brain glioma cells U251, U87 and U118, the pseudolaric acid B with the concentration of 25umol/L and 50umol/L has smaller toxicity to human umbilical vein epithelial cells HUVEC, and can also effectively kill the human brain glioma cells.
TABLE 4 proliferation inhibition of human umbilical vein epithelial cells HUVEC by pseudolaric acid B
EXAMPLE 3 study of the mechanism of action of pseudolaric acid on human glioma cells
(1) Activation of autophagy flow in human brain glioma cells by pseudolaric acid B
In order to clarify the action mechanism of pseudolaric acid on human glioma cells, 50umol/L of pseudolaric acid is adopted for the experiment, and incubated with human glioma cells U87 for 6, 12, 24 and 48 hours, and the protein is extracted, and then the expression of autophagy-related proteins is detected by a Westernblotting method, so that the result is shown in FIG. 5, the pseudolaric acid can up-regulate the expression of protein ATG5 and protein LC3B II in a time-dependent manner, and simultaneously, the expression of autophagy substrate protein P62 is correspondingly inhibited. The red-green tandem fluorescent LC3B protein plasmid is transfected into human brain glioma cells U87 by adopting slow viruses, and whether autophagy is induced by pseudolaric acid B is further verified. As a result, as shown in FIG. 6, after 50umol/L of pseudolaric acid B had acted for 48 hours, red, green and yellow spots appeared in U87 cells, and red fluorescent spots were significantly increased as compared with the control group. From this, it was demonstrated that pseudolaric acid B activated autophagy flow in human glioma cells.
(2) Cortex pseudolaricis propionic acid kills human brain glioma cells by activating autophagy
To illustrate the effect of autophagy in killing human glioma cells by using pseudolaric acid B, the experiment uses an autophagy-initiated inhibitor 3MA (with the concentration of 5 mmol/L) and an autophagy flow inhibitor, namely, bafulomycin A1 (with the concentration of 0.2 umol/L), to incubate with human glioma cells U87 for 1h, then 50umol/L of pseudolaric acid B is added, and after 48h of action, the death of the cells is detected by using an LDH release method, and the results are shown in FIG. 7, both 3MA and Bafulomycin A1 can effectively inhibit the death of human glioma cells induced by the pseudolaric acid B. After extracting the protein, the protein is analyzed by a Westernblotting method, and the result is shown in figure 8, 3MA effectively inhibits the increase of protein LC3B II induced by pseudolaric acid B and the decrease of autophagy substrate protein P62; the baffiamycin A1 further increases the level of protein LC3B II while inhibiting the decrease of autophagy substrate protein P62. From this, it was demonstrated that pseudolaric acid B kills human brain glioma cells by activating autophagy.
EXAMPLE 4 proliferation inhibition of Hibiscus syriacus bark propionic acid on human liver cancer cells
In order to verify that the pseudolaric acid B can kill other malignant tumor cells such as human liver cancer cells, the experiment inoculates the human liver cancer cells Hep3B into a DMEM culture medium in a 96-well plate, incubates the culture medium with carbon dioxide overnight, incubates the culture medium with the pseudolaric acid B (12.5 umol/L, 25umol/L, 50umol/L, 100umol/L and 200 umol/L) with different concentrations for 48 hours, and then adopts an MTT method to detect the proliferation capability of the cells. As shown in FIG. 9 and Table 5, the survival rates of human hepatoma cell Hep3B were reduced to 98.37%, 94.82%, 81.62%, 56.02% and 40.10%, respectively. Therefore, the pseudolaric acid B can kill human liver cancer cells in a concentration-dependent manner.
Table 5 proliferation inhibition of Hibiscus syriacus propionic acid on human liver cancer cell Heb3B (: p < 0.01)
EXAMPLE 5 proliferation inhibition of Hibiscus Pi Bingsuan on breast cancer cells
In order to verify that pseudolaric acid B can kill other malignant tumor cells such as human breast cancer cells, the experiment inoculates human breast cancer cells MB-231 into DMEM culture medium in a 96-well plate, and incubates the cells with different concentrations of pseudolaric acid B (12.5 umol/L, 25umol/L, 50umol/L, 100umol/L, 200 umol/L) for 48 hours, and then adopts an MTT method to detect the proliferation capacity of the cells. The results are shown in FIG. 10 and Table 6, and the survival rates of human breast cancer cells MB-231 are respectively reduced to: 94.02%, 88.34%, 75.90%, 58.83%, 43.87%. Thus, pseudolaric acid can kill human breast cancer cells in a concentration-dependent manner.
TABLE 6 proliferation inhibition of human breast cancer cells MB-231 by pseudolaric acid (p < 0.01)
EXAMPLE 6 proliferation inhibition of Hibiscus syriacus bark propionic acid on human ovarian cancer cells
To verify that pseudolaric acid can kill other types of malignant tumor cells such as human ovarian cancer cells, the experiment inoculates human ovarian cancer cells A2780 into DMEM medium in a 96-well plate, incubates the cells with different concentrations of pseudolaric acid (12.5 umol/L, 25umol/L, 50umol/L, 100umol/L, 200 umol/L) overnight, and then tests the proliferation capacity of the cells by MTT method. As shown in fig. 11 and table 7, the survival rates of human ovarian cancer cells a2780 decreased to: 93.78%, 87.34%, 71.82%, 55.64%, 41.39%. Thus, pseudolaric acid can kill human ovarian cancer cells in a concentration-dependent manner.
TABLE 7 proliferation inhibition of human ovarian cancer cells A2780 by pseudolaric acid B (.: p < 0.01)
The invention discloses an application of pseudolaric acid B in preparing a medicament for preventing and/or treating malignant tumor, and a person skilled in the art can properly improve process parameters by referring to the content of the pseudolaric acid B. It is expressly noted that all such similar substitutions and modifications will be apparent to those skilled in the art, and are deemed to be included in the present invention. While the invention has been described with reference to preferred embodiments, it will be apparent to those skilled in the relevant art that variations and modifications can be made in the invention described herein without departing from the spirit or scope of the invention.
Claims (4)
1. Use of pseudolaric acid for the preparation of a medicament for the prevention and/or treatment of a malignancy, wherein the malignancy is selected from the group consisting of: glioma, liver cancer, breast cancer and ovarian cancer.
2. The use according to claim 1, wherein the concentration of the pseudolaric Pi Bing acid is from 12.5 to 200umol/L.
3. The use according to claim 2, wherein the concentration of the pseudolaric Pi Bing acid is 25-50 umol/L.
4. The use according to claim 3, wherein the concentration of the pseudolaric Pi Bing acid is 25umol/L.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210318949.0A CN114668757B (en) | 2022-03-29 | 2022-03-29 | Application of pseudolaric acid B in preparing medicine for preventing and/or treating malignant tumor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210318949.0A CN114668757B (en) | 2022-03-29 | 2022-03-29 | Application of pseudolaric acid B in preparing medicine for preventing and/or treating malignant tumor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114668757A CN114668757A (en) | 2022-06-28 |
| CN114668757B true CN114668757B (en) | 2023-08-08 |
Family
ID=82075572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210318949.0A Active CN114668757B (en) | 2022-03-29 | 2022-03-29 | Application of pseudolaric acid B in preparing medicine for preventing and/or treating malignant tumor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114668757B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1361106A (en) * | 2000-12-29 | 2002-07-31 | 中国人民武装警察部队医学院 | Corter pseudolaricis acetic acid derivative and its medicinal composite and their antineoplastic and antifungal application |
| CN1961896A (en) * | 2006-11-28 | 2007-05-16 | 赵因 | Effective part of Chinese medicinal pseudolarix in inhibiting angiogenesis |
| CN101062026A (en) * | 2006-04-24 | 2007-10-31 | 黑龙江大学 | Function of pseudolarix acetic acid as medicine for inducing tumor cells to die |
| CN102219772A (en) * | 2011-06-20 | 2011-10-19 | 东莞广州中医药大学中医药数理工程研究院 | Cortex pseudolaricis acid complex with bioactivity and preparation method thereof |
| CN102408403A (en) * | 2011-09-26 | 2012-04-11 | 宋云龙 | Pseudolarix acid derivatives as well as preparation method and application thereof |
| CN113230249A (en) * | 2021-05-07 | 2021-08-10 | 广州中医药大学(广州中医药研究院) | Application of pseudolaric acid B in serving as or preparing Hedgehog signal path inhibitor |
-
2022
- 2022-03-29 CN CN202210318949.0A patent/CN114668757B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1361106A (en) * | 2000-12-29 | 2002-07-31 | 中国人民武装警察部队医学院 | Corter pseudolaricis acetic acid derivative and its medicinal composite and their antineoplastic and antifungal application |
| CN101062026A (en) * | 2006-04-24 | 2007-10-31 | 黑龙江大学 | Function of pseudolarix acetic acid as medicine for inducing tumor cells to die |
| CN1961896A (en) * | 2006-11-28 | 2007-05-16 | 赵因 | Effective part of Chinese medicinal pseudolarix in inhibiting angiogenesis |
| CN102219772A (en) * | 2011-06-20 | 2011-10-19 | 东莞广州中医药大学中医药数理工程研究院 | Cortex pseudolaricis acid complex with bioactivity and preparation method thereof |
| CN102408403A (en) * | 2011-09-26 | 2012-04-11 | 宋云龙 | Pseudolarix acid derivatives as well as preparation method and application thereof |
| CN113230249A (en) * | 2021-05-07 | 2021-08-10 | 广州中医药大学(广州中医药研究院) | Application of pseudolaric acid B in serving as or preparing Hedgehog signal path inhibitor |
Non-Patent Citations (1)
| Title |
|---|
| Comparative Study on the Content and Cytotoxicity of Pseudolaric Acid B in the Five Plant Parts of Pseudolarix kaempferi;Agung Nugroho，等;《Natural Product Sciences》;第23卷(第4期);265-269 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114668757A (en) | 2022-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xia et al. | Vorinostat upregulates MICA via the PI3K/Akt pathway to enhance the ability of natural killer cells to kill tumor cells | |
| Cheng et al. | Metformin inhibits the tumor-promoting effect of low-dose resveratrol, and enhances the anti-tumor activity of high-dose resveratrol by increasing its reducibility in triple negative breast cancer | |
| CN114469987B (en) | Application of bacteroides fragilis zwitterionic capsular polysaccharide and immune checkpoint inhibitor combined drug to treatment of genitourinary system tumor | |
| CN116115617A (en) | Anti-lung cancer medicine and application thereof | |
| CN114668757B (en) | Application of pseudolaric acid B in preparing medicine for preventing and/or treating malignant tumor | |
| Bornstein et al. | Arsenic Trioxide inhibits the growth of human ovarian carcinoma cell line | |
| Liu et al. | HTBPI, an active phenanthroindolizidine alkaloid, inhibits liver tumorigenesis by targeting Akt | |
| CN102266341A (en) | Application of pyrazolopyrimidine compounds in preparing medicines for treating lung cancer | |
| CN108295085B (en) | Application of protodioscin in preparation of drug-resistant osteosarcoma drug | |
| WO2020087938A1 (en) | Use of spleen tyrosine kinase as therapeutic target of intrahepatic cholangiocarcinoma | |
| Xu et al. | Benzalkonium bromide as a new potential instillation drug for bladder cancer: hypothesis and pilot study | |
| CN102633668B (en) | Use of compound in therapeutic drug for diseases related to disorder of transcription factor | |
| CN110790639A (en) | Compound for treating colorectal cancer | |
| US20180289676A1 (en) | Compounds and methods targeting gper in cancer | |
| CN114652750B (en) | Application of traditional Chinese medicine composition in preparation of colorectal cancer prevention medicines | |
| CN111265665B (en) | Pharmaceutical composition for treating cervical cancer and pharmaceutical application thereof | |
| CN117298074A (en) | Application of tetrahydromagnolol in preparation of medicines for preventing and/or treating tumors | |
| CN110124057A (en) | A kind of anti-tumor drug or pharmaceutical carrier of the cyclodextrin comprising glutamine modification | |
| CN108635493A (en) | Antitumor and cirsoid pharmaceutical composition for the treatment of and its preparation method and application | |
| CN116492321B (en) | Antitumor pharmaceutical composition and application thereof | |
| CN1287796C (en) | Composition of epigallocatechin, gallate and folic acid and its use | |
| CN102824334A (en) | Anti-cancer drug | |
| RU2273502C1 (en) | Method for treating the cases of ovarian carcinoma relapse | |
| CN110433172B (en) | Medicine with effect of treating non-small cell lung cancer and application thereof | |
| US20210246127A1 (en) | Compounds and methods targeting gper for treatment of diseases associated with calcium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |